ZSH‐2208: A novel retinoid with potent anti‐tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis
The ESCC-TRCs replicates the characteristics of ESCC stem cells, which are inhibited by ZSH-2208. In vivo and in vitro experiments demonstrated that ZSH-2208, a novel RA analogue, effectively inhibits the growth of ESCC-TRCs through the RARγ-TNFAIP3 axis. Low levels of TNFIP3 protein may be associated with improved survival probability in ESCC patients.
Authors
- Heng Jiao (ORCID: https://orcid.org/0000-0003-3805-9465)
- Junjie Ni (ORCID: https://orcid.org/0000-0002-2982-1668)
- Quan‐Lin Li (ORCID: https://orcid.org/0000-0002-9108-8786)
- Xin Cao (ORCID: https://orcid.org/0000-0003-1722-023X)
- Jiayun Hou
- Wenrui Zhao
- Xuan Huang (ORCID: https://orcid.org/0000-0002-6635-8297)
- Ruoxue Chen
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- South China Institute of Collaborative Innovation (CN)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1002/ctm2.70148
- Citations
- 1
- Primary Topic
- Retinoids in leukemia and cellular processes
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- National Natural Science Foundation of China
- Fudan University
- National Key Research and Development Program of China